Drug interactions
Ciltacabtagene autoleucel + Obinutuzumab
Severity: Major
Ciltacabtagene autoleucel and Obinutuzumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Obinutuzumab causes B-cell depletion and neutropenia with a risk of serious infection. Ciltacabtagene autoleucel is a BCMA-directed CAR T therapy associated with prolonged cytopenias and infections. Together they may increase infectious complications.
What this interaction means in plain words
Ciltacabtagene autoleucel and Obinutuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ciltacabtagene autoleucel belongs to Miscellaneous; Obinutuzumab belongs to Oncology.
Why it happens
Additive immunosuppression and myelosuppression.
What to do
Avoid concurrent use and follow the CAR T product's guidance on timing. Monitor blood counts and for infection, and consider immunoglobulin replacement.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ciltacabtagene autoleucel and Obinutuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Other interactions of Ciltacabtagene autoleucel
Frequently asked questions
Can I take Ciltacabtagene autoleucel with Obinutuzumab?
MediHelp rates the interaction as major. Ciltacabtagene autoleucel and Obinutuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Obinutuzumab causes B-cell depletion and neutropenia with a risk of serious infection. Ciltacabtagene autoleucel is a BCMA-directed CAR T therapy associated with prolonged cytopenias and infections. Together they may increase infectious complications.
How serious is the interaction between Ciltacabtagene autoleucel and Obinutuzumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use and follow the CAR T product's guidance on timing. Monitor blood counts and for infection, and consider immunoglobulin replacement.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
